Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRRX NASDAQ:FHTX NASDAQ:LENZ NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AFHTXFoghorn Therapeutics$3.73-0.3%$4.54$3.27▼$6.95$219.59M2.89162,936 shs118,964 shsLENZLENZ Therapeutics$7.01-2.6%$8.69$6.61▼$50.40$225.75M0.58833,180 shs493,911 shsSGMTSagimet Biosciences$6.76-4.2%$6.59$4.50▼$11.41$230.05M3.41755,949 shs608,190 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT0.00%0.00%0.00%0.00%+230.45%FHTXFoghorn Therapeutics-0.27%-12.85%-20.30%-35.47%-11.19%LENZLENZ Therapeutics-2.64%-9.90%-27.58%-39.93%-75.98%SGMTSagimet Biosciences-4.25%-7.27%-19.33%+24.95%+65.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AFHTXFoghorn Therapeutics$3.73-0.3%$4.54$3.27▼$6.95$219.59M2.89162,936 shs118,964 shsLENZLENZ Therapeutics$7.01-2.6%$8.69$6.61▼$50.40$225.75M0.58833,180 shs493,911 shsSGMTSagimet Biosciences$6.76-4.2%$6.59$4.50▼$11.41$230.05M3.41755,949 shs608,190 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRRXDURECT0.00%0.00%0.00%0.00%+230.45%FHTXFoghorn Therapeutics-0.27%-12.85%-20.30%-35.47%-11.19%LENZLENZ Therapeutics-2.64%-9.90%-27.58%-39.93%-75.98%SGMTSagimet Biosciences-4.25%-7.27%-19.33%+24.95%+65.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRRXDURECT 2.00HoldN/AN/AFHTXFoghorn Therapeutics 2.88Moderate Buy$11.43206.40% UpsideLENZLENZ Therapeutics 2.50Moderate Buy$29.80325.11% UpsideSGMTSagimet Biosciences 2.64Moderate Buy$25.57278.28% UpsideCurrent Analyst Ratings BreakdownLatest DRRX, SGMT, FHTX, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026SGMTSagimet Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$35.00 ➝ $12.005/13/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $20.005/12/2026LENZLENZ Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$39.00 ➝ $12.005/12/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $38.005/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/21/2026FHTXFoghorn Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59FHTXFoghorn Therapeutics$30.91M7.08N/AN/A($1.92) per share-1.94LENZLENZ Therapeutics$20.99M10.47N/AN/A$9.09 per share0.77SGMTSagimet Biosciences$2M110.12N/AN/A$3.42 per share1.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%N/AFHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)LENZLENZ Therapeutics-$82.13M-$3.60N/AN/AN/A-519.30%-46.82%-43.32%7/29/2026 (Estimated)SGMTSagimet Biosciences-$51.04M-$1.34N/AN/AN/AN/A-37.57%-35.52%8/12/2026 (Estimated)Latest DRRX, SGMT, FHTX, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SGMTSagimet Biosciences-$0.39-$0.33+$0.06-$0.33N/AN/A5/11/2026Q1 2026LENZLENZ Therapeutics-$1.10-$1.32-$0.22-$1.32$1.76 million$1.90 million5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million3/24/2026Q4 2025LENZLENZ Therapeutics-$0.91-$1.16-$0.25-$1.16$3.09 million$1.59 million3/11/2026Q4 2025FHTXFoghorn Therapeutics-$0.30-$0.34-$0.04-$0.34$9.50 million$9.25 million3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRRXDURECTN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRRXDURECTN/A0.980.95FHTXFoghorn TherapeuticsN/A2.922.92LENZLENZ TherapeuticsN/A10.4010.26SGMTSagimet BiosciencesN/A20.3320.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRRXDURECT28.03%FHTXFoghorn Therapeutics61.55%LENZLENZ Therapeutics54.32%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipDRRXDURECT3.20%FHTXFoghorn Therapeutics7.58%LENZLENZ Therapeutics8.30%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRRXDURECT8031.05 million30.06 millionOptionableFHTXFoghorn Therapeutics12058.71 million54.26 millionOptionableLENZLENZ Therapeutics11031.35 million28.75 millionN/ASGMTSagimet Biosciences832.58 million27.80 millionOptionableDRRX, SGMT, FHTX, and LENZ HeadlinesRecent News About These CompaniesHere's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom FisherJune 4 at 10:56 AM | zacks.comSagimet Biosciences Grants New Performance-Based Executive Equity AwardsJune 3 at 6:10 PM | tipranks.comSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASHMay 27, 2026 | globenewswire.comSagimet Biosciences Inc - Ordinary Shares - Series AMay 21, 2026 | money.usnews.comWall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to TradeMay 21, 2026 | zacks.comSagimet Biosciences (SGMT) price target increased by 15.00% to 29.86May 15, 2026 | msn.comSagimet Biosciences: Making The Bull Case For Differentiated DenifanstatMay 14, 2026 | seekingalpha.comSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 13, 2026 | globenewswire.comSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 12, 2026 | globenewswire.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from JonesTradingMay 11, 2026 | theglobeandmail.comSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in ChicagoMay 11, 2026 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on ThursdayMay 7, 2026 | marketbeat.comSagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?May 5, 2026 | zacks.comDoes Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?May 5, 2026 | zacks.comSagimet Biosciences stock surges 30% on acne trial plansApril 28, 2026 | au.investing.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 40.04%April 28, 2026 | aaii.comASagimet Biosciences Shares Jump 30% on Acne Trial Expansion PlansApril 28, 2026 | finance.yahoo.comWhy Is Sagimet Biosciences Stock Trading Higher On Monday?April 27, 2026 | benzinga.comSagimet Updates Investor Presentation After Key Clinical MilestonesApril 27, 2026 | tipranks.comSagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 MillionApril 27, 2026 | quiverquant.comQSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRRX, SGMT, FHTX, and LENZ Company DescriptionsDURECT NASDAQ:DRRXDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Foghorn Therapeutics NASDAQ:FHTX$3.73 -0.01 (-0.27%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.72 0.00 (-0.13%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.LENZ Therapeutics NASDAQ:LENZ$7.01 -0.19 (-2.64%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$7.01 +0.00 (+0.01%) As of 06/5/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Sagimet Biosciences NASDAQ:SGMT$6.76 -0.30 (-4.25%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$6.92 +0.16 (+2.29%) As of 06/5/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
